Host: Janine Austin Clayton, MD Guest: A. Paul Chous, MA, OD, FAAO, CDE Guest: Anne Peters, MD Guest: Charles Wykoff, MD, PhD Even though diabetic retinopathy is the leading cause of blindness among U.S. adults, a substantial number of patients with diabetes are not receiving routine eye exams and are at risk of vision loss. Making matters worse is the fact that many patients with diabetes remain unaware that this disease can affect their vision. That’s why this discussion with a panel of expert faculty will examine what it means to be proactive in promoting vision screening and minimizing the risk for vision loss with appropriate early treatment in these patients. Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

Diabetes Discourse

Diabetic Retinopathy: Understanding the Impact on Patient Lives and the Need for Timely Diagnosis and Referral

Host: Janine Austin Clayton, MD Guest: A. Paul Chous, MA, OD, FAAO, CDE Guest: Anne Peters, MD When it comes to protecting the vision of our patients with diabetes, the importance of taking assertive action cannot be ignored. But another key aspect that can unfortunately be easy to overlook is care collaboration. Featuring Dr. Janine Clayton, Dr. A. Paul Chous, and Dr. Anne Peters, this discussion will focus on how providers can work together to optimize patients’ eye health and minimize their risk of vision loss from diabetic retinopathy and diabetic macular edema. Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

In Plain Sight: Evaluating All Patients with Diabetes for Diabetic Retinopathy

Host: Anne Peters, MD Guest: Thomas W. Gardner, MD, MS Guest: Diana Shechtman, OD, FAAO Unfortunately, there are many factors that can contribute to a patient’s risk for vision-threatening complications and vision loss due to diabetes. Explore those factors with Dr. Anne Peters, Dr. Thomas Gardner, and Dr. Diana Shechtman, who also discuss how endocrinologists and primary care providers can work together with eye care professionals to actively optimize vision outcomes for patients at risk for diabetic retinopathy and diabetic macular edema. Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

On the Frontline of Diabetic Retinopathy: Assessment of High-Risk Patient Populations

Guest: Regina Benjamin, MD, MS As healthcare providers, it’s our duty to emphasize the importance of preventing the eye-health consequences associated with diabetes, particularly as it pertains to health disparities and underserved populations. This activity featuring Dr. Regina Benjamin serves as a call to action by discussing the essential roles that all healthcare professionals play in the overall eye-health of our patients to reduce visual impairment due to diabetic retinopathy. Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

A Call to Action from Regina Benjamin, MD, the 18th U.S. Surgeon General

Guest: Michael H. Davidson, MD Tune in as Dr. Michael Davidson, a preventive cardiologist from the University of Chicago Pritzker School of Medicine, outlines what a diabetes cardiovascular outcomes trial (CVOT) is, the differences between CVOTs and glycemic efficacy trials, and how these studies are designed and assessed. US19HCP00067 July 2019

Diabetes Cardiovascular Outcomes Trials: What You Need to Know

Host: Jennifer Caudle, DO Guest: Christie Ballantyne, MD With the number of patients with both type 2 diabetes and established cardiovascular disease on the rise, a personalized patient approach to treating these two conditions is now more important than ever. Joining Dr. Jennifer Caudle to discuss the role of the cardiologist in managing patients with type 2 diabetes is Dr. Christie Ballantyne. US18VZ00285 January 2019

Role of the Cardiologist in T2D Management

Host: Jennifer Caudle, DO Guest: Mikhail Kosiborod, MD Guest: Christie Ballantyne, MD Since type 2 diabetes and cardiovascular disease often go hand in hand, having a care collaboration plan in place is essential in managing these conditions. Here to discuss both the challenges and opportunities that arise when collaborating patient care are cardiologists Dr. Mikhail Kosiborod and Dr. Christie Ballantyne. US18VZ00286 January 2019

Care Collaboration: Patients with Type 2 Diabetes & Established Cardiovascular Disease – The Cardiologists' Perspective

Host: John J. Russell, MD Guest: Candis Morello, PharmD, CDE Candis M Morello, Professor of Clinical Pharmacy at UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, joins Dr. John Russell to talk about team-based care integrations of certified diabetes educators to help empower diabetes patients and improve long-term outcomes. Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only. Brought to you by 

The Role of the Certified Diabetes Educator: A Team Effort

Host: John J. Russell, MD Guest: Candis Morello, PharmD, CDE Host Dr. John Russell welcomes Candis M. Morello, PharmD., CDE, FCSHP, Professor of Clinical Pharmacy and Associate Dean for Student Affairs at the Skaggs School of Pharmacy and Pharmaceutical Sciences. Dr. Morello explains the importance of patient education, communication, and motivation needed to instill a positive and healthy approach to diabetes care. Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only. Brought to you by 

Toward a Healthier Journey for the Type 2 Diabetes Patient

Host: John J. Russell, MD Guest: Neil Skolnik, MD For clinicians managing patients with T2DM, the clinical landscape for standards of care, diagnostic methods and techniques, and treatment options has become increasingly complex. Yet despite this challenge in keeping up to date with the latest recommendations, updated practice guidelines have also made it a point to emphasize "big picture" elements in diabetes care, reinforcing mainstays of treatment that can potentially get overlooked. On this episode, Dr. John Russell welcomes diabetes expert Dr Neil Skolnik, Associate Director of Family Medicine at Abington Jefferson Health, to explore the "Back to Basics" model in diabetes management, with emphasis on individualized therapeutic approaches and lifestyle modification strategies for improving long-term patient outcomes. Diabetes Discourse, a non-certified educational series, is brought to you by AstraZeneca, pushing the boundaries of science to create life-changing medicines for people with diabetes. Content of this diabetes education is produced and solely controlled by ReachMD. This series is intended for healthcare professionals only. Brought to you by 

Fostering a "Back to Basics" Model in Type 2 Diabetes Care

Guest: Paresh Dandona, MD, PhD Host: Farhad Zangeneh, MD Host Dr. Farhad Zangeneh welcomes Paresh Dandona MD, PhD, Professor and Chief of Endocrinology in the Department of Medicine at the University of Buffalo. His Specialty and Research Focus are in Endocrinology, Diabetes and Metabolism. He is also the Founder & Medical Director of the Diabetes-Endocrinology Center of Western New York. In this program, Dr. Dandona will be discussing insulin induced cardioprotection, inflammatory and oxidative stress in acute myocardial infarction. He will also review hyperglycemia and cardiotoxicity in acute myocardial infarction. Please take a listen!  

Anti-inflammatory, Anti-atherogenic and Cardioprotective Effects of Insulin

Guest: Robert A. Rizza, MD Host: Farhad Zangeneh, MD What are the sources of glucose in the body? Is diabetes a pancreatic disease or a hepatic disease? What is the importance of glucose toxicity in Type 1 or Type 2 diabetes patients? To answer these questions and many more, join our host Dr. Farhad Zangenh in a discussion with Dr. Robert Rizza, an authority in the regulation of carbohydrate metabolism in humans, and the Executive Dean for Research at Mayo Clinic. Download the podcast and listen in!

Physiologic Fundamentals of Impaired Glucose Metabolism

Host: Farhad Zangeneh, MD Guest: Paul Jellinger In diabetes management, clinicians typically measure glycemic control with fasting plasma glucose (FPG) and premeal glucose measurements, and HbA1c. And, the goals for each of these measurements have been established based on the results of many clinical trials. However, the majority of patients with diabetes fail to achieve these glycemic goals. Elevated postprandial glucose (PPG) concentrations may contribute to suboptimal glycemic control. Host Dr Farhad Zangeneh is joined by Dr. Paul Jellinger who will address the issue of postprandial glucose and its complications. Paul S. Jellinger, MD and Master of the American College of Endocrinology (MACE) serves as Professor of Medicine on the voluntary faculty at the University of Miami and served as Chief of the Section of Endocrinology at Memorial Regional Hospital in Hollywood, Florida. Dr. Jellinger served as president of the AACE, the ACE and the Florida Endocrine Society. Dr. Jellinger has been active on the AACE Board of Directors.

Postprandial Blood Glucose: Diabetes Control & Complications

Guest: Yehuda Handelsman, MD Host: Farhad Zangeneh, MD Dr Farhad Zangeneh is joined by Dr. Yehuda Handelsman, Medical Director at the Metabolic Institute of America; President of the American Association of Clinical Endocrinologists; and, Chair & Program Director, "Annual World Congress on Insulin Resistance, Diabetes & CVD". Dr. Handelsman will discuss the recent growing concerns between diabetes, anti-diabetes agents, and the increased prevalence of various cancers. Currently available data are limited, controversial, and confusing. The AACE and health care providers believe that this is a critically important area that needs further clarification.

Growing Concerns of Diabetes and Various Cancers

Guest: James R. Gavin, III, MD, PhD Host: Farhad Zangeneh, MD Host Dr Farhad Zangeneh welcomes James R. Gavin III, MD, PhD, clinical professor of medicine at Emory University School of Medicine and at the Indiana University School of Medicine. Together they will explore the trends in the growth of diabetes in African Americans, the policies needed to address these problems, and some of the barriers that prevent better outcomes in diabetes care for African Americans and other high-risk minorities. James R. Gavin III, MD AND PHD, clinical professor of medicine at Emory University School of Medicine and at the Indiana University School of Medicine. Dr. Gavin serves as CEO and Chief Medical Officer of Healing Our Village, Inc. He also belongs to a number of organizations, including the Institute of Medicine, the American Diabetes Association (ADA), the American Society of Clinical Investigation, the American Association of Physicians, and the Atlanta Rotary Club. 

Diabetes Health Care Disparities in the African American Community

The prevalence of type 2 diabetes has increased to more than 8% of the US population, and this growth trend is expected to continue. Advances in diabetes care remain at the forefront of treatment. Diabetes Discourse features the latest developments, from new insulin therapies to exciting research and promising technology.

hubhopper

Diabetes Discourse

hubhopper